Drugs / ASN004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04410224 | Apr 2022 → May 2024 | cancer | Kirilys Therapeutics Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-10-24 | Asana BioSciences | Results Asana BioSciences to Present Updates on its Oncology Development Pipeline at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics asanabio.com ↗
ASN004, a novel 5T4-targeted Dolaflexin ADC, causes complete and durable tumor regressions in a variety of tumor xenograft models. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-04-01 | Asana BioSciences | Asana BioSciences announces dosing of first patient in Phase 1 trial of ASN004, a novel 5T4-Antibody-Drug-Conjugate asanabio.com ↗ |
| 2017-10-24 | Asana BioSciences | Asana BioSciences to Present Updates on its Oncology Development Pipeline at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics asanabio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASN004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04410224 ↗ |
| Modality | Other / unclassified | “ASN004 is an antibody-drug conjugate” NCT04410224 ↗ |
| Route | Intravenous | “receive ASN004 once every 3 or 4 weeks by intravenous infusion” NCT04410224 ↗ |